552 related articles for article (PubMed ID: 25865094)
21. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
Ozbek B; Otük G
Int J Antimicrob Agents; 2010 Aug; 36(2):191-2. PubMed ID: 20537868
[No Abstract] [Full Text] [Related]
22. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
Vandepitte WP; Berge J; Andersson R
J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
[TBL] [Abstract][Full Text] [Related]
26. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
[TBL] [Abstract][Full Text] [Related]
27. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
29. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.
Pogue JM; Mann T; Barber KE; Kaye KS
Expert Rev Anti Infect Ther; 2013 Apr; 11(4):383-93. PubMed ID: 23566148
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex.
Huang YS; Wang JT; Sheng WH; Chuang YC; Chang SC
J Microbiol Immunol Infect; 2015 Oct; 48(5):545-51. PubMed ID: 24662017
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.
Dinc G; Demiraslan H; Elmali F; Ahmed SS; Alp E; Doganay M
New Microbiol; 2015 Jan; 38(1):67-73. PubMed ID: 25742149
[TBL] [Abstract][Full Text] [Related]
33. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
[TBL] [Abstract][Full Text] [Related]
34. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.
Zilberberg MD; Kollef MH; Shorr AF
J Hosp Med; 2016 Jan; 11(1):21-6. PubMed ID: 26353076
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.
Ku NS; Lee SH; Lim YS; Choi H; Ahn JY; Jeong SJ; Shin SJ; Choi JY; Choi YH; Yeom JS; Yong D; Song YG; Kim JM
Sci Rep; 2019 Nov; 9(1):17127. PubMed ID: 31748527
[TBL] [Abstract][Full Text] [Related]
36. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
[TBL] [Abstract][Full Text] [Related]
37. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
[TBL] [Abstract][Full Text] [Related]
39. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an
Beganovic M; Daffinee KE; Luther MK; LaPlante KL
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006
[No Abstract] [Full Text] [Related]
40. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
Pei G; Mao Y; Sun Y
Microb Drug Resist; 2012 Dec; 18(6):574-7. PubMed ID: 22928863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
